LumiQuick Diagnostics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LumiQuick Diagnostics is a commercial-stage, private diagnostics company offering a diverse portfolio of rapid lateral flow tests and ELISA kits. Its product lines target human health (infectious diseases, cardiac markers, fertility, drugs of abuse), veterinary/food safety, and environmental/biothreat detection, leveraging a core immunochromatography technology platform. The company has achieved commercial traction, notably with an FDA EUA for its Boson Rapid SARS-CoV-2 Antigen Home Test, and operates in a competitive but expansive global rapid diagnostics market. Its strategy involves broadening its test menu and leveraging its QuickProfile and EnviroSafe brands across multiple sectors.

Infectious DiseaseCardiologyOncologyWomen's HealthToxicologyVeterinary Health

Technology Platform

Core platform is immunochromatography (lateral flow) and Enzyme-Linked Immunosorbent Assay (ELISA/EIA) for the development of rapid point-of-care and laboratory-based diagnostic tests.

Opportunities

The growing global demand for decentralized, rapid diagnostics across human health, veterinary medicine, and biodefense presents a significant expansion opportunity.

Leveraging its existing FDA EUA regulatory experience can accelerate entry into new regulated markets with additional test offerings.

Risk Factors

The company faces intense competition from large, established diagnostics firms and numerous agile startups.

Regulatory pathways for new tests are costly and uncertain, and reliance on a broad portfolio subjects it to shifting demand in multiple, sometimes volatile, market segments.

Competitive Landscape

LumiQuick operates in the highly competitive rapid diagnostics market, competing against global giants like Abbott (BinaxNOW), QuidelOrtho, and Roche, as well as many smaller specialized companies. Its strategy of broad diversification across disease areas and species (human/veterinary) is a key differentiator but requires competing effectively on multiple fronts simultaneously.

More companies in Diagnostics & Precision Medicine →More companies in United States →